Vanguard Group Inc. Has $275.62 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Vanguard Group Inc. boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,258,963 shares of the biopharmaceutical company’s stock after purchasing an additional 458,143 shares during the quarter. Vanguard Group Inc. owned 9.79% of Amicus Therapeutics worth $275,619,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Xponance Inc. grew its holdings in shares of Amicus Therapeutics by 11.9% in the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 2,249 shares during the period. KBC Group NV lifted its holdings in Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 3,120 shares in the last quarter. Swiss National Bank grew its stake in Amicus Therapeutics by 0.7% in the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company’s stock valued at $4,121,000 after acquiring an additional 3,200 shares during the period. Legacy Capital Group California Inc. increased its holdings in shares of Amicus Therapeutics by 20.2% in the fourth quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics during the third quarter worth about $55,000.

Analysts Set New Price Targets

Several brokerages recently issued reports on FOLD. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Wells Fargo & Company dropped their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Price Performance

NASDAQ:FOLD opened at $7.50 on Friday. The stock’s 50-day simple moving average is $9.12 and its 200 day simple moving average is $9.86. Amicus Therapeutics, Inc. has a 52-week low of $7.39 and a 52-week high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a market cap of $2.30 billion, a P/E ratio of -41.67, a P/E/G ratio of 1.51 and a beta of 0.69.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.